Found 7 matching trials
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NASingle-arm, prospective, open-label feasibility study evaluating the techni...
Location
King Hussein Cancer Center
Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL
PHASE2This is a Prospective Single Center, open label, Non-randomized, Single Arm...
Location
King Hussein Cancer Center
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NAThe goal of this Long-Term Follow-Up Trial is to assess long-term safety an...
Location
Charité Universitätsmedizin Berlin
MB-CART19.1 in Patients With R/R ALL
PHASE2Precursor-B acute lymphoblastic leukemia (ALL) is the most common cancer in...
Location
Multiple Locations
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
PHASE1This is a phase l multi-centric, single arm, prospective open, dose-escalat...
Status
Active Not Recruiting
Location
Charité - University clinic, pediatric clinic with focus on oncology and hematology
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
PHASE1This study will test whether MB-CART19.1 is a safe and effective treatment ...
Location
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
MB-CART19.1 in Refractory SLE
PHASE1This is a phase l/ll open-label, multicentre, interventional single-arm tri...
Location
Universitätsklinikum Erlangen, Medizinische Klinik 3